Cbt Ar Arfid denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for cbt ar arfid are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies CBT-AR for ARFID as Duplicate Therapy — and Why You Can Appeal

CBT-AR (Cognitive Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder) is a structured, disorder-specific psychotherapy protocol designed for ARFID. A duplicate-therapy denial from Humana means the plan has determined that the patient is already receiving a behavioral health service it considers equivalent. This denial is often incorrect: general CBT, supportive therapy, or nutrition counseling is not clinically equivalent to CBT-AR, which uses a distinct treatment model, specific session structure, and intervention components developed specifically for the ARFID diagnosis.

## Why This Is Appealable

For a duplicate-therapy denial to stand, Humana must identify a specific covered service the patient is actively receiving that is clinically equivalent to CBT-AR for ARFID. If the concurrent service is a different modality, addresses a different diagnosis, or lacks the ARFID-specific components of CBT-AR, the denial lacks a clinical foundation. The prescriber's letter and a side-by-side comparison of the two treatments' goals and methods is typically sufficient to defeat this denial.

## Federal Appeal Framework

• Internal appeal: Submit within the deadline on the denial letter. Under ERISA §503 (self-funded) or state law (fully insured), Humana must conduct a full-and-fair review of submitted clinical evidence.
• External review: Under ACA §2719, an independent IRO can review whether the duplicate-therapy determination was clinically supported. The general window is approximately four months from the original denial — use the exact deadline on your denial letter.
• Mental Health Parity: If the same clinical uniqueness standard would not be applied to a comparable physical-health therapy, a parity argument may further strengthen the appeal.
• Expedited review: Request simultaneously with the internal appeal if delay would worsen the patient's condition.

## Documentation to Gather

1. ARFID diagnosis documentation — DSM-5 diagnostic assessment confirming ARFID, with differentiation from other feeding/eating disorders. 2. Description of all current behavioral health services — dates, provider, modality, and treatment goals for any concurrent therapy, demonstrating it is not CBT-AR and does not address ARFID specifically. 3. CBT-AR treatment plan — from the prescribing clinician, explaining the specific protocol, session structure, and how it differs from any current service. 4. Prescriber medical-necessity letter — must directly rebut the duplicate-therapy finding by identifying the clinical distinctions between CBT-AR and whatever service Humana cited.

## Criteria-Mapping Structure

Request from Humana the specific policy provision and the service they identified as the claimed duplicate. Copy that provision verbatim. In the adjacent column, document the clinical differences between CBT-AR and the identified service. This direct rebuttal is the core of the appeal.

## Next Step

If Humana's denial letter does not name the specific service it considers a duplicate, send a written request for that information before or simultaneously with filing your appeal.